evoke semaglutide trial Novo Nordisk said Monday that an older oral version of its diabetes treatment, semaglutide, failed to meet its main goal in late-stage trials assessing whether it could slow cognitive decline in Alzheimer's Data from the Evoke trials

It should not be considered a substitute for PRP, stem cell therapies, or advanced image-guided musculoskeletal treatments

Overall, GLP-1 receptor agonists reduced major adverse CV events by 14% (HR = 0.86

Until recently, those medications meant having to give yourself an injection

Small meals that contain low-fat foods may also aid in abating the nausea

This information is typically used by the Medical Review Officer (MRO)a licensed physician who reviews positive resultsto verify the use of a prescribed controlled substance

Saskatchewan announced in March 2026 that it will review GLP-1 obesity coverage as part of its 2027 formulary update, the first province to formally reconsider the category